share_log

Barclays Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $43

Benzinga ·  Oct 7 14:42  · Ratings

Barclays analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and raises the price target from $42 to $43.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment